Prognostic potential of an immune score based on the density of CD8(+) T cells, CD20(+) B cells, and CD33(+)/p-STAT1(+) double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients.
Prognostic potential of an immune score based on the density of CD8(+) T cells, CD20(+) B cells, and CD33(+)/p-STAT1(+) double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients.
复制标题
基于 IIIA 期胃癌患者癌巢内 CD8 T 细胞、CD20 B 细胞和 CD33 /p-STAT1 双阳性细胞密度以及 HMGB1 表达的免疫评分的预后潜力
DOI：
10.21147/j.issn.1000-9604.2016.05.10
复制
发表时间：
2016-10
期刊：
影响因子：
--
通讯作者：
Zhang X
中科院分区：
文献类型：
--
作者：
Dong J;Li J;Liu S;Feng X;Chen S;Zhou Z;Chen Y;Zhang X
目的胃癌TNM分期的预后存在异质性.本研究评估了免疫评分系统作为TNM分期系统补充的预后潜力。方法采用免疫组织化学方法检测100例IIIA期胃癌患者癌组织中T细胞、B细胞和髓源性抑制细胞（MDSCs）的密度，并检测癌细胞中高迁移率族蛋白B1（HMGB1）的表达。分析总生存期（OS）、无病生存期（DFS）与免疫学指标的关系。结果根据肿瘤组织中T细胞、B细胞、MDSC密度和HMGB1表达的预后作用建立了免疫评分系统。本组患者的中位5年生存率为32%。然而，根据免疫评分系统，免疫评分为4至0的患者的5年生存率分别为80.0%、51.7%、0%、5.8%和0%。同样，在免疫评分亚组中观察到DFS率的差异。结论免疫评分系统可以有效地识别IIIA期胃癌患者的预后异质性，提示该免疫评分系统可能是TNM分期系统的潜在补充，并有助于在预后的基础上识别更同质的患者进行辅助治疗。
Objective There is heterogeneity in the prognosis of gastric cancers staged according to the tumornodes- metastasis (TNM) system. This study evaluated the prognostic potential of an immune score system to supplement the TNM staging system. Methods An immunohistochemical analysis was conducted to assess the density of T cells, B cells, and myeloid-derived suppressor cells (MDSCs) in cancer tissues from 100 stage IIIA gastric cancer patients; the expression of the high-mobility group protein B1 (HMGB1) was also evaluated in cancer cells. The relationship between the overall survival (OS), disease-free survival (DFS), and immunological parameters was analyzed. Results An immune score system was compiled based on the prognostic role of the density of T cells, B cells, MDSCs, and the expression of HMGB1 in cancer tissues. The median 5-year survival of this group of patient was 32%. However, the 5-year survival rates of 80.0%, 51.7%, 0%, 5.8%, and 0% varied among the patients with an immune score of 4 to those with an immune score of 0 based on the immune score system, respectively. Similarly, differences in DFS rates were observed among the immune score subgroups. Conclusions An immune score system could effectively identify the prognostic heterogeneity within stage IIIA gastric cancer patients, implying that this immune score system may potentially supplement the TNM staging system, and help in identifying a more homogeneous group of patients who on the basis of prognosis can undergo adjuvant therapy.
登录
查看更多内容
影响因子：
7.4
作者：
Galon J;Pagès F;Marincola FM;Angell HK;Thurin M;Lugli A;Zlobec I;Berger A;Bifulco C;Botti G;Tatangelo F;Britten CM;Kreiter S;Chouchane L;Delrio P;Arndt H;Asslaber M;Maio M;Masucci GV;Mihm M;Vidal-Vanaclocha F;Allison JP;Gnjatic S;Hakansson L;Huber C;Singh-Jasuja H;Ottensmeier C;Zwierzina H;Laghi L;Grizzi F;Ohashi PS;Shaw PA;Clarke BA;Wouters BG;Kawakami Y;Hazama S;Okuno K;Wang E;O'Donnell-Tormey J;Lagorce C;Pawelec G;Nishimura MI;Hawkins R;Lapointe R;Lundqvist A;Khleif SN;Ogino S;Gibbs P;Waring P;Sato N;Torigoe T;Itoh K;Patel PS;Shukla SN;Palmqvist R;Nagtegaal ID;Wang Y;D'Arrigo C;Kopetz S;Sinicrope FA;Trinchieri G;Gajewski TF;Ascierto PA;Fox BA
通讯作者：
Fox BA
影响因子：
--
作者：
Bergman MP;D'Elios MM
通讯作者：
D'Elios MM
DOI：
10.1007/s12032-012-0442-2
发表时间：
2013-03
期刊：
Medical oncology (Northwood, London, England)
影响因子：
--
作者：
Dong J;Li J;Liu SM;Feng XY;Chen S;Chen YB;Zhang XS
通讯作者：
Zhang XS
影响因子：
10.6
作者：
Kang, Rui;Chen, Ruochan;Zhang, Qiuhong;Hou, Wen;Wu, Sha;Cao, Lizhi;Huang, Jin;Yu, Yan;Fan, Xue-gong;Yan, Zhengwen;Sun, Xiaofang;Wang, Haichao;Wang, Qingde;Tsung, Allan;Billiar, Timothy R.;Zeh, Herbert J., III;Lotze, Michael T.;Tang, Daolin
通讯作者：
Tang, Daolin
影响因子：
14.5
作者：
Ostrand-Rosenberg S;Sinha P;Beury DW;Clements VK
通讯作者：
Clements VK